ASCO GU 2022 Updates: PARP Inhibitors in First-Line and Subsequent UC Settings

Video

Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022.

Recent Videos
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content
Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

AI-Based Urine Test Earns FDA Breakthrough Device Status in Bladder Cancer

Russ Conroy
July 1st 2025
Article

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
March 4th 2025
Podcast

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.

FDA Approves Mitomycin Solution in Low-Grade Intermediate-Risk NMIBC

Russ Conroy
June 12th 2025
Article

Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Matthew Fowler;Jun Gong, MD
March 15th 2022
Podcast

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Silas Inman
June 3rd 2025
Article

A combination of BCG and mitomycin offers a comparable treatment option to BCG monotherapy for NMIBC, potentially lessening the impact of global BCG shortages.

Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

Ben Saylor
May 31st 2025
Article

Sasanlimab plus BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients, with notable benefit in carcinoma in situ and T1 tumors.